Antonio Vigano

Antonio Vigano, MD, MSc
Associate Professor, Departments of Oncology and Medicine, McGill University
Director, McGill Nutrition and Performance Laboratory (
vigano.antonio [at] (Email)
Through a Canadian Foundation for Innovation award, Antonio Vigano founded the McGill Nutrition and Performance Laboratory. The research and clinical activities at MNUPAL were developed in partnership with the Department of Exercise Science at Concordia University (Robert Kilgour), the Division of Geriatric Medicine (Jose Morais), the Department of Surgery (Prosanto Chaudhury) and the Lymphedema Program (Anna Towers) at the McGill University Health Centre. These activities aim to improve the classification, diagnosis, treatment and prevention of wasting and/or debilitating syndromes such as cachexia, sarcopenia and lymphedema, primarily in patients suffering from cancer and/or frailty. Current research interests at MNUPAL include: validation of tools for assessing nutrition and performance in advanced cancer patients; definition of relationships between molecular, nutritional and functional correlates of cancer cachexia; diagnosis and treatment of male hypogonadism in advanced cancer; prediction and prevention of surgical risks in elderly cancer patients; evaluation of body composition in lymphedema.

Selected Publications

Vigano AL, di Tomasso J, Kilgour RD, Trutschnigg B, Lucar E, Morais JA, Borod M. The abridged patient-generated subjective global assessment is a useful tool for early detection and characterization of cancer cachexia.  J Acad Nutr Diet. 2014 Jul;114(7):1088-98.

Trutschnigg B, Kilgour RD, Morais JA, Lucar E, Hornby L, Molla H, Vigano A. Metabolic, nutritional and inflammatory characteristics in elderly women with advanced cancer. J Geriatr Oncol. 2013 Apr;4(2):183-9.

Newman AL, Rosenthall L, Towers A, Hodgson P, Shay CA, Tidhar D, Vigano A, Kilgour RD. Determining the precision of dual energy x-ray absorpiometry and bioelectric impedance spectroscopy in the assessment of breast cancer-related lymphedema.  Lymphat Res Biol. 2013 Jun;11(2):104-9.

Vigano A, Del Fabbro E, Bruera E, Borod M. The cachexia clinic:  from staging to managing nutritional and functional problems in advanced cancer patients. Crit Rev Oncog. 2012;17(3):293-303.

Tan BH, Fladvad T, Braun TP, Vigano A, Strasser F, Deans DA, Skipworth RJ, Solheim TS, Damaraju S, Ross JA, Kaasa S, Marks DL, Baracos VE, Skorpen F, Fearon KC; European Palliative Care Research Collaborative. P-selectin genotype is associated with the development of cancer cachexia.  EMBO Mol Med. 2012 Jun;4(6):462-71.

Scheede-Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, Vigano A. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012 Feb;31(1):85-8.

Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA. Cancer-related fatigue:  the impact of skeletal muscle mass and strength in patients with advanced.  J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):177-185.

Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R. Male hypogonadism associated with advanced cancer:  a systematic review. Lancet Oncol. 2010 Jul;11(7):679-84.

Vigano A, Piccioni B, Trutschnigg L, Hornby P, Chaudhury RD, and Kilgour RD. Functional, Nutritional and Quality of Life Correlates of Hypogonadism in Advanced Cancer: A Qualitative Systematic Review of the Literature. Lancet Oncol. 2010 Jul;11(7):679-84

Vigano A, Trutschnigg B, Kilgour RD, Hamel N, Hornby L, Lucar E, Foulkes W, Tremblay M, and Morais JA. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. Clin Cancer Res. 2009 Apr 1;15(7):2442-7.

Rosenthall L, Trutschnigg B, and Vigano A. An analysis of the precision of total body and regional tissue measurements by dual-energy X-ray absorptiometry. Int J Body Compos Res. 2008 Vol. 6 No. 3: 108–113.

Trutschnigg B, Kilgour RD, Reinglas J, Rosenthall L, Hornby L, Morais JA, and Vigano A. Precision and reliability of strength (Jamar vs. Biodex handgrip) and body composition (dual-energy X-ray absorptiometry vs. bioimpedance analysis) measurements in advanced cancer patients. Appl Physiol Nutr Metab. 2008 Dec;33(6):1232-9.

Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, and Kaasa S. Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations—A Study by the Steering Committee of the European Association for Palliative Care. Journal of Clinical Oncology, Vol 23, No 25 (September 1), 2005: pp. 6240-6248.

Fainsinger R, Nekolaichuk C, Lawlor P, Neumann C, Hansen J, and Vigano A. The Revised Edmonton Staging System for Cancer Pain. J Pain Symptom Manage. 2005 Mar;29(3):224-237